Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 04, 2025 08:30 ET | Source: NeurAxis, Inc.

NeurAxis to Host Third Quarter 2025 Results and Business Update Call on Tuesday, November 11, 2025

CARMEL, Ind., Nov. 04, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing...
October 16, 2025 08:19 ET | Source: Biomerica, Inc.

Henry Schein and Biomerica Enter into Marketing Services Agreement for Biomerica’s inFoods® IBS Test in the U.S.

- Expands Marketing of Non-Drug IBS Symptom Management Test Through One of the Nation’s Most Trusted Health Care Distributors- Relationship Marks a Key Milestone in Biomerica’s Commercialization...
September 18, 2025 08:00 ET | Source: NeurAxis, Inc.

NeurAxis to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025

CARMEL, Ind., Sept. 18, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies...
September 09, 2025 08:08 ET | Source: Biomerica, Inc.

Biomerica Launches AI-Backed inFoods® IBS Trigger Food Navigator to Support Personalized IBS Therapy and Improve Patient Outcomes

New AI-enabled digital tool empowers patients to confidently manage IBS symptoms and avoid the trigger foods identified by inFoods® IBS testingIBS affects an estimated 40 million adults in the U.S....
August 12, 2025 07:00 ET | Source: NeurAxis, Inc.

NeurAxis Reports Strong Second Quarter 2025 Financial Results Driven by a 46% Growth in Revenues

CARMEL, Ind., Aug. 12, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for...
August 05, 2025 08:30 ET | Source: NeurAxis, Inc.

NeurAxis to Host Second Quarter 2025 Results and Business Update Call on Tuesday, August 12, 2025

CARMEL, Ind., Aug. 05, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing...
June 17, 2025 08:00 ET | Source: NeurAxis, Inc.

NeurAxis Announces New Medical Policy Coverage with Two Health Insurers, Adding 700,000 Covered Lives

CARMEL, Ind., June 17, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing...
June 10, 2025 08:00 ET | Source: NeurAxis, Inc.

NeurAxis Achieves Critical Milestone; Secures Key Academic Society Guidelines Recommendation for Treatment of Functional Abdominal Pain (FAP) in IBS

Practice guidelines published in the Journal of Pediatric Gastroenterology & Nutrition (JPGN) name Percutaneous Electrical Nerve Field Stimulation (PENFS) as a recommended treatment option for FAP...
May 27, 2025 08:00 ET | Source: NeurAxis, Inc.

NeurAxis to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025

CARMEL, Ind., May 27, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing...
May 22, 2025 13:03 ET | Source: NeurAxis, Inc.

NeurAxis Announces Closing of $5.0 Million Registered Direct Offering

CARMEL, Ind., May 22, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing...